OncoMatch/Clinical Trials/NCT07189195
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
Is NCT07189195 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TR-002 for advanced malignant solid neoplasm.
Treatment: TR-002 — This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable), that has spread from where it first started (primary site) to other places in the body (metastatic) and unresectable or metastatic pancreatic adenocarcinoma that does not respond to treatment (refractory). Chemotherapy drugs, such as TR-002, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. TR-002 may be safe and tolerable in treating patients with advanced, unresectable or metastatic solid tumors and unresectable or metastatic, refractory pancreatic adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Pancreatic Cancer
Disease stage
Required: Stage III, IV (AJCC v8)
metastatic or unresectable solid tumor; for expansion cohort, metastatic or unresectable pancreatic adenocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 75,000/mcL; Hemoglobin ≥ 8g/dL
Kidney function
Creatinine ≤ 1.5 x institutional ULN OR GFR ≥ 60 mL/min/1.73 m^2
Liver function
Total bilirubin ≤ 1.5 x institutional ULN (< 3 x ULN in patients with known Gilberts); AST/ALT ≤ 3 × institutional ULN (< 5 x ULN in patients with known liver metastases)
Cardiac function
Adequate cardiac function, assessed by MUGA or echocardiography (LVEF > 50%)
Adequate cardiac function, assessed by multiple-gated acquisition (MUGA) scan or echocardiography (left ventricular ejection fraction of > 50%) Absolute neutrophil count ≥ 1,000/mcL Platelets ≥ 75,000/mcL Hemoglobin ≥ 8g/dL Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (< 3 x ULN in patients with known Gilberts) AST/ALT ≤ 3 × institutional ULN (< 5 x ULN in patients with known liver metastases) Creatinine ≤ 1.5 x institutional ULN OR GFR ≥ 60 mL/min/1.73 m^2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify